Get the Stockscreener App
3.45
1.43%
-0.05
After Hours:
3.45
Phio Pharmaceuticals Corp stock is traded at $3.45, with a volume of 31,779.
It is down -1.43% in the last 24 hours and up +26.84% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$3.50
Open:
$3.61
24h Volume:
31,779
Relative Volume:
0.68
Market Cap:
$3.05M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.3397
EPS:
-10.156
Net Cash Flow:
$-11.09M
1W Performance:
+0.58%
1M Performance:
+26.84%
6M Performance:
-43.63%
1Y Performance:
-74.61%
1-Day Range:
$3.45
$3.74
1-Week Range:
$3.32
$3.74
52-Week Range:
$2.40
$29.07
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
PHIOPhio Pharmaceuticals Corp. Latest Stock News & Market Updates - StockTitan
This trade activity should not be overlooked: Hyliion Holdings Corporation (HYLN) - SETE News
INTASYL Technology and Compounds to be Focus of Presentation at 20th - North Bay Nugget
INTASYL Technology and Compounds to be Focus of Presentation at 20th - Shoreline Beacon
INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society - Newsfile
INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society - StockTitan
HITE Hedge Asset Management LLC Sells 12,931 Shares of PHINIA Inc. (NYSE:PHIN) - MarketBeat
Hyliion Holdings Corporation (HYLN) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4% - MarketBeat
Financial Metrics Unveiled: P3 Health Partners Inc (PIII)’s Key Ratios in the Spotlight - The Dwinnex
Does Hyliion Holdings Corporation (NYSE: HYLN) Still Need To Convince Analysts? - Stocks Register
Barrow Hanley Mewhinney & Strauss LLC Purchases Shares of 898,419 Helios Technologies, Inc. (NASDAQ:HLIO) - MarketBeat
Hancock Whitney Corp Buys 10,920 Shares of PHINIA Inc. (NYSE:PHIN) - MarketBeat
PHINIA Inc. (NYSE:PHIN) Shares Acquired by Long Road Investment Counsel LLC - Defense World
King Luther Capital Management Corp Boosts Position in Helios Technologies, Inc. (NASDAQ:HLIO) - Defense World
Texas Permanent School Fund Corp Has $1.39 Million Stock Holdings in PHINIA Inc. (NYSE:PHIN) - Defense World
Thailand's new celebrity baby pygmy hippo, Moo Deng - The Business Standard
Bokf Na Has $58,000 Stock Position in Haleon plc (NYSE:HLN) - Defense World
American Century Companies Inc. Raises Position in PHINIA Inc. (NYSE:PHIN) - Defense World
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Wiarton Echo
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Owen Sound Sun Times
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Nanton News
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - High River Times
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Melfort Journal
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - StockTitan
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA - StockTitan
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA - Invezz
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA - Newsfile
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA - Yahoo Finance
Contrasting Clearmind Medicine (NASDAQ:CMND) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Devon Dispatch
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Nanton News
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - North Bay Nugget
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Newsfile
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Phio Pharmaceuticals (NASDAQ:PHIO) Trading Down 0.8% - Defense World
Phio Pharmaceuticals Corp. (NASDAQ:PHIO): Is Breakeven Near? - Simply Wall St
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Yahoo Finance
Phio Pharmaceuticals Corp.'s (NASDAQ:PHIO) Path To Profitability - Yahoo Finance
Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - GlobeNewswire Inc.
Phio Pharmaceuticals (NASDAQ:PHIO) Posts Earnings Results, Beats Estimates By $0.97 EPS - Defense World
Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update - Newsfile
Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update - Quantisnow
Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan
Short Interest in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Rises By 178.0% - Defense World
PHIO stock touches 52-week low at $2.4 amid market challenges - Investing.com
Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound - Markets Insider
Phio Pharmaceuticals Announces Exploratory Collaboration with a - Airdrie Echo
Phio Pharmaceuticals Announces Exploratory Collaboration with a - The Kingston Whig-Standard
Phio Pharmaceuticals Announces Exploratory Collaboration with a - Shoreline Beacon
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):